Literature DB >> 27317583

Association of the von Willebrand Factor-ADAMTS13 Ratio With Incident Cardiovascular Events in Patients With Peripheral Arterial Disease.

David Green1, Lu Tian2, Philip Greenland3, Kiang Liu3, Melina Kibbe4,5, Russell Tracy6, Sanjiv Shah1, John T Wilkins1,3, Mark D Huffman1,3, Yihua Liao3, Donald Lloyd Jones1,3, Mary M McDermott1,3.   

Abstract

BACKGROUND: Platelet adhesion is mediated by von Willebrand factor (vWF), and disintegrin-like and metalloprotease domain with thrombospondin type-1 motif, number 13 (ADAMTS13) is a protease that cleaves vWF. A change in the balance between vWF and ADAMTS13 in favor of thrombosis might occur shortly before ischemic cardiovascular (CV) events.
OBJECTIVE: To determine whether vWF, ADAMTS13, and the ratio of vWF and ADAMTS13 change during the months preceding an acute CV event.
DESIGN: Prospective longitudinal observational study.
SETTING: Outpatient. PATIENTS: A total of 595 participants with peripheral artery disease (PAD). MEASUREMENTS: Blood samples were obtained every 2 months for up to 3 years and hemostatic factors examined at intervals preceding events.
RESULTS: Sixty-one participants (cases) experienced events and were matched to 122 PAD controls. During the 2-month interval prior to an event, cases (n = 48) had higher levels of the vWF and ADAMTS13 than controls (n = 95; P = .05), but significance was lost after adjusting for the baseline differences in myocardial infarction, unstable angina, and stroke. During the 10 months prior to an event, median values for vWF and the ratio of vWF and ADAMTS13 were higher in cases than in controls, but the differences were not statistically significant. However, in a subset of 20 patients with complete bimonthly data, there was a trend toward an increase in the ratio in the 10 months prior to a CV event ( P = .04).
CONCLUSION: In patients with PAD experiencing an ischemic CV event, a significant increase in the ratio of vWF to ADAMTS13 prior to the event could not be confirmed, although there was a weak trend in this direction.

Entities:  

Keywords:  ADAMTS13 protein; biomarkers; human; ischemic stroke; myocardial infarction; peripheral vascular disease; von Willebrand factor

Mesh:

Substances:

Year:  2016        PMID: 27317583      PMCID: PMC6689399          DOI: 10.1177/1076029616655615

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  27 in total

1.  Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators.

Authors:  A R Folsom; W D Rosamond; E Shahar; L S Cooper; N Aleksic; F J Nieto; M L Rasmussen; K K Wu
Journal:  Circulation       Date:  1999-08-17       Impact factor: 29.690

2.  Changes in von Willebrand factor and soluble ICAM, but not soluble VCAM, soluble E selectin or soluble thrombomodulin, reflect the natural history of the progression of atherosclerosis.

Authors:  A D Blann; G Y H Lip; C N McCollum
Journal:  Atherosclerosis       Date:  2002-12       Impact factor: 5.162

3.  von Willebrand factor and coronary heart disease: prospective study and meta-analysis.

Authors:  P H Whincup; J Danesh; M Walker; L Lennon; A Thomson; P Appleby; A Rumley; G D O Lowe
Journal:  Eur Heart J       Date:  2002-11       Impact factor: 29.983

4.  Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia.

Authors:  Gregor Theilmeier; Carine Michiels; Erik Spaepen; Ingrid Vreys; Désiré Collen; Jos Vermylen; Marc F Hoylaerts
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

5.  Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins.

Authors:  P André; C V Denis; J Ware; S Saffaripour; R O Hynes; Z M Ruggeri; D D Wagner
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

6.  Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation.

Authors:  Takashi Uemura; Koichi Kaikita; Hiroshige Yamabe; Kenji Soejima; Masakazu Matsukawa; Shunichiro Fuchigami; Yasuaki Tanaka; Kenji Morihisa; Koji Enomoto; Hitoshi Sumida; Seigo Sugiyama; Hisao Ogawa
Journal:  Thromb Res       Date:  2008-11-08       Impact factor: 3.944

Review 7.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2008-07-01       Impact factor: 22.113

8.  Hemostasis, inflammation, and fatal and nonfatal coronary heart disease: long-term follow-up of the atherosclerosis risk in communities (ARIC) cohort.

Authors:  Anna M Kucharska-Newton; David J Couper; James S Pankow; Ronald J Prineas; Thomas D Rea; Nona Sotoodehnia; Aravinda Chakravarti; Aaron R Folsom; David S Siscovick; Wayne D Rosamond
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-01       Impact factor: 8.311

9.  Multi-Ethnic Study of Atherosclerosis: objectives and design.

Authors:  Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy
Journal:  Am J Epidemiol       Date:  2002-11-01       Impact factor: 4.897

10.  Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack.

Authors:  J T B Crawley; D A Lane; M Woodward; A Rumley; G D O Lowe
Journal:  J Thromb Haemost       Date:  2008-01-11       Impact factor: 5.824

View more
  4 in total

Review 1.  Biomarkers and Genetics in Peripheral Artery Disease.

Authors:  Surovi Hazarika; Brian H Annex
Journal:  Clin Chem       Date:  2016-11-21       Impact factor: 8.327

2.  von Willebrand factor/ADAMTS13 ratio at presentation of acute ischemic brain injury is predictive of outcome.

Authors:  Alice Taylor; Chiara Vendramin; Deepak Singh; Martin M Brown; Marie Scully
Journal:  Blood Adv       Date:  2020-01-28

3.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

4.  Effect of Acute Myocardial Infarction on a Disintegrin and Metalloprotease with Thrombospondin Motif 13 and Von Willebrand Factor and Their Relationship with Markers of Inflammation.

Authors:  Abeer A Al-Masri; Syed Shahid Habib; Ahmad Hersi; Hana Al Zamil
Journal:  Int J Vasc Med       Date:  2020-02-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.